Alice S Mims, MD
Leadership Title: Co-Leader, Leukemia and Hematologic Malignancies Program
Academic Title: Professor in the College of Medicine
Research Program: Leukemia and Hematologic Malignancies
About Me
More info forI am a hematologist who specializes in treating patients suffering from acute and chronic myeloid diseases, particularly acute myeloid leukemia (AML). I was named to the Castle Connolly list of “Regional Top Doctors” in 2019, as well as being rated in the top 10 percent of physicians in the nation for patient satisfaction in 2017. I received my medical degree and Master of Science in Clinical Research (MSCR) from the Medical University of South Carolina and then completed a combined fellowship in medical oncology/translational research here at The Ohio State University, where I currently serve as an assistant professor in the Division of Hematology. During my fellowship, I received the Conquer Cancer Foundation Young Investigator Award, the American Society of Hematology Clinical Research Training Institute Award and a T32 Research Training Grant from the National Institutes of Health. Since I’ve been on faculty, I have received the American Society of Hematology Clinical Scholar Award and the Alliance Foundation Clinical Scholar Award, both for research support. As a member of the Leukemia and Hematologic Malignancies Program at the OSUCCC – James, my research interests include studying the effectiveness of novel therapeutics on patients with AML and other myeloid neoplasms. I have authored multiple clinical trial proposals in AML and have been the site principal investigator (PI) for investigator-initiated and industry-supported AML studies in both upfront and relapsed/refractory disease. I am currently the lead PI on a multi-center study investigating novel treatment in elderly AML patients though the Leukemia & Lymphoma Society Beat AML Master Trial. Additionally, my work has been published in several well-respected journals, including Molecular Pharmacology, Leukemia and Blood. I feel privileged to be part of the Ohio State medical community, and I’m especially proud to contribute to the work we do here at the OSUCCC – James. We all share a common goal: to provide cutting-edge research that will lead to a cancer-free world and deliver superior, individualized care to each and every one of our patients.
Clinical Expertise
More info for- Myelodysplastic Syndromes
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Acute Myeloid Leukemias
- Leukemia, Myeloid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
Where I See Patients
More info forThe Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
460 W. 10th Ave. Columbus, Ohio 43210 800-293-5066 Location InformationEducation & Training
More info forMedical School
- Medical University of South Carolina College of Medicine
41 Bee St, Charleston, SC
Fellowship - Hematology & Oncology
- Ohio State University Wexner Medical Center
700 Ackerman Rd, Columbus, OH
Residency - Internal Medicine
- Wake Forest University Baptist Medical Center
1 Medical Center Blvd, Winston Salem, NC
- Medical University of South Carolina College of Medicine
Academic Office & Contact Information
More info forAcademic Office:
The James Outpatient Care 7268
2121 Kenny Rd
Columbus, Ohio 43221Email:
mims.18@osu.eduReviews
More info forPatient Satisfaction Review
The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our
Patient Satisfaction Survey page The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.
Videos
More info forPublications
More info forOctober 12, 2024Combination ruxolitinib and belumosudil is tolerable and induces responses despite treatment failure as monotherapies.
Caputo J, Peddireddi A, Bhatta S, Huang Y, Bezerra E, Brammer J, Larkin K, Mims A, Vasu S, Wall S, Choe H
Leuk Lymphoma
October 4, 2024Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia.
Stiff A, Fornerod M, Kain BN, Nicolet D, Kelly BJ, Miller KE, Mrózek K, Boateng I, Bollas A, Garfinkle EAR, Momoh O, Fasola FA, Olawumi HO, Mencia-Trinchant N, Kloppers JF, van Marle AC, Hu E, Wijeratne S, Wheeler G, Walker CJ, Buss J, Heyrosa A, Desai H, Laganson A, Hamp E, Abu-Shihab Y, Abaza H, Kronen P, Sen S, Johnstone ME, Quinn K, Wronowski B, Hertlein E, Miles LA, Mims AS, Oakes CC, Blachly JS, Larkin KT, Mundy-Bosse B, Carroll AJ, Powell BL, Kolitz JE, Stone RM, Duarte C, Abbott D, Amaya ML, Jordan CT, Uy GL, Stock W, Archer KJ, Paskett ED, Guzman ML, Levine RL, Menghrajani K, Chakravarty D, Berger MF, Bottomly D, McWeeney SK, Tyner JW, Byrd JC, Salomonis N, Grimes HL, Mardis ER, Eisfeld AK
Nat Genet
September 16, 2024White blood cell count levels are associated with inflammatory response and constitute independent outcome predictors in adult patients with acute myeloid leukemia aged <60 years.
Ozga M, Nicolet D, Mrózek K, Walker CJ, Blachly JS, Kohlschmidt J, Orwick S, Carroll AJ, Larson RA, Kolitz JE, Powell BL, Stone RM, Byrd JC, Eisfeld AK, Mims AS
Am J Hematol
September 10, 2024Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A multi-institutional study.
Badar T, Narra R, Mims AS, Heckman MG, Shallis RM, Fahad S, Hunter C, Kota V, Othman TA, Jonas B, Desai S, de Camargo Correia GS, Patel A, DuVall AS, Palmisiano N, Curran E, Omer Z, Advani A, Atallah E, Litzow M
Am J Hematol
August 7, 2024Beat-AML 2024 ELN-Refined Risk Stratification for Older Adults with Newly Diagnosed AML Given Lower-Intensity Therapy.
Hoff FW, Blum W, Huang Y, Welkie RL, Swords R, Traer E, Stein EM, Lin TL, Archer KJ, Patel PA, Collins RH, Baer MR, Duong VH, Arellano ML, Stock W, Odenike O, Redner RL, Kovacsovics TJ, Deininger MW, Zeidner JF, Olin RL, Smith CC, Foran JM, Schiller GJ, Curran E, Koenig KL, Heerema NA, Chen TL, Martycz M, Stefanos M, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate U, Mims AS, Byrd JC, Madanat YF
Blood Adv
June 12, 2024Impact of chronic graft-versus-host disease on non-relapse mortality and survival.
Jiang J, Sigmund AM, Zhao Q, Elder P, Vasu S, Jaglowski S, Mims A, Choe H, Larkin K, Wall S, Grieselhuber N, William B, Penza S, Benson DM, Efebera YA, Sharma N
Leuk Lymphoma
May 3, 2024Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model.
Archer KJ, Fu H, Mrózek K, Nicolet D, Mims AS, Uy GL, Stock W, Byrd JC, Hiddemann W, Braess J, Spiekermann K, Metzeler KH, Herold T, Eisfeld AK
J Hematol Oncol
April 28, 2024Determining the relationship of p16INK4a and additional molecular markers of aging with clinical frailty in hematologic malignancy.
Rosko AE, Elsaid MI, Woyach J, Islam N, Lepola N, Urrutia J, Christian LM, Presley C, Mims A, Burd CE
J Cancer Surviv
April 22, 2024Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia.
Elgamal OA, Fobare S, Vibhute S, Mehmood A, Vroom DC, Johnson ML, Stearns B, Lerma JR, Truxall J, Stahl E, Carmichael B, Orwick SJ, Mims AS, Curran E, Santhanam R, Tridandapani S, Phelps MA, Xie Z, Coss CC, Baker SD, Patrick J, Ezzell JK, Rai J, Pan J, Rai SN, Stillwell C, Wunderlich M, Abdulrahim M, Goodwin TE, Hilinski G, Bennett CE, Hertlein E, Byrd JC
JCI Insight
March 27, 2024Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML).
Cortes J, Jonas BA, Schiller G, Mims A, Roboz GJ, Wei AH, Montesinos P, Ferrell PB, Yee KW, Fenaux P, Schwarer A, Watts JM
Leuk Lymphoma
March 4, 2024The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling.
Marr AR, Halpin M, Corbin DL, Asemelash Y, Sher S, Gordon BK, Whipp EC, Mitchell S, Harrington BK, Orwick S, Benrashid S, Goettl VM, Yildiz V, Mitchell AD, Cahn O, Mims AS, Larkin KTM, Long M, Blachly J, Woyach JA, Lapalombella R, Grieselhuber NR
Exp Hematol Oncol
November 28, 2023Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG).
Ozga M, Nicolet D, Mrózek K, Yilmaz AS, Kohlschmidt J, Larkin KT, Blachly JS, Oakes CC, Buss J, Walker CJ, Orwick S, Jurinovic V, Rothenberg-Thurley M, Dufour A, Schneider S, Sauerland MC, Görlich D, Krug U, Berdel WE, Woermann BJ, Hiddemann W, Braess J, Subklewe M, Spiekermann K, Carroll AJ, Blum WG, Powell BL, Kolitz JE, Moore JO, Mayer RJ, Larson RA, Uy GL, Stock W, Metzeler KH, Grimes HL, Byrd JC, Salomonis N, Herold T, Mims AS, Eisfeld AK
Leukemia
October 23, 2023A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
Cai SF, Huang Y, Lance JR, Mao HCC, Dunbar A, McNulty S, Druley TE, Li Y, Baer MR, Stock W, Kovacsovics T, Blum W, Schiller GJ, Olin RL, Foran JM, Litzow MR, Lin TL, Patel PA, Foster MC, Boyiadzis M, Collins RH, Chervin J, Shoben AB, Vergilio JA, Heerema NA, Rosenberg L, Chen TL, Yocum AO, Druggan F, Marcus S, Stefanos M, Druker BJ, Mims AS, Borate U, Burd A, Byrd JC, Levine RL, Stein EM
Blood Adv
September 21, 2023Treating acute myelogenous leukemia in patients aged 70 and above: Recommendations from the International Society of Geriatric Oncology (SIOG).
Extermann M, Artz A, Rebollo MA, Klepin HD, Krug U, Loh KP, Mims AS, Neuendorff N, Santini V, Stauder R, Vey N, SIOG
J Geriatr Oncol
September 4, 2023Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia.
Bhatnagar B, Zhao Q, Mims AS, Vasu S, Behbehani GK, Larkin K, Blachly JS, Badawi MA, Hill KL, Dzwigalski KR, Phelps MA, Blum W, Klisovic RB, Ruppert AS, Ranganathan P, Walker AR, Garzon R
Leuk Lymphoma
August 30, 2023Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia.
Ravandi F, Bashey A, Foran JM, Stock W, Mawad R, Short NJ, Yilmaz M, Kantarjian HM, Odenike O, Patel AA, Garcha R, Ainsworth WB, Clynes R, Kanodia J, Ding Y, Li H, Kye S, Mims AS
Blood Adv
August 28, 2023Real-world genomic testing and treatment patterns of newly diagnosed adult acute myeloid leukemia patients within a comprehensive health system.
Byrd JC, Gatz JL, Louis CL, Mims AS, Borate U, Yocum AO, Gana TJ, Burd A
Cancer Med
August 9, 2023Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.
Shallis RM, Daver N, Altman JK, Komrokji RS, Pollyea DA, Badar T, Bewersdorf JP, Bhatt VR, de Botton S, de la Fuente Burguera A, Carraway HE, Desai P, Dillon R, Duployez N, El Chaer F, Fathi AT, Freeman SD, Gojo I, Grunwald MR, Jonas BA, Konopleva M, Lin TL, Mannis GN, Mascarenhas J, Michaelis LC, Mims AS, Montesinos P, Pozdnyakova O, Pratz KW, Schuh AC, Sekeres MA, Smith CC, Stahl M, Subklewe M, Uy GL, Voso MT, Walter RB, Wang ES, Zeidner JF, Žucenka A, Zeidan AM
Lancet Haematol
May 17, 2023Association of social deprivation with survival in younger adult patients with AML: an Alliance study.
Rebechi M, Kohlschmidt J, Mrózek K, Nicolet D, Mims AS, Blachly JS, Orwick S, Larkin K, Oakes CC, Hantel A, Carroll AJ, Blum W, Powell BL, Uy GL, Stone RM, Larson RA, Byrd JC, Paskett ED, Plascak JJ, Eisfeld AK
Blood Adv
May 1, 2023Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology.
Pollyea DA, Altman JK, Assi R, Bixby D, Fathi AT, Foran JM, Gojo I, Hall AC, Jonas BA, Kishtagari A, Lancet J, Maness L, Mangan J, Mannis G, Marcucci G, Mims A, Moriarty K, Mustafa Ali M, Neff J, Nejati R, Olin R, Percival ME, Perl A, Przespolewski A, Rao D, Ravandi F, Shallis R, Shami PJ, Stein E, Stone RM, Sweet K, Thota S, Uy G, Vachhani P, Cassara CJ, Freedman-Cass DA, Stehman K
J Natl Compr Canc Netw
April 20, 2023Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
Duong VH, Ruppert AS, Mims AS, Borate U, Stein EM, Baer MR, Stock W, Kovacsovics T, Blum W, Arellano ML, Schiller GJ, Olin RL, Foran JM, Litzow MR, Lin TL, Patel PA, Foster MC, Redner RL, Al-Mansour Z, Cogle CR, Swords RT, Collins RH, Vergilio JA, Heerema NA, Rosenberg L, Yocum AO, Marcus S, Chen T, Druggan F, Stefanos M, Gana TJ, Shoben AB, Druker BJ, Burd A, Byrd JC, Levine RL, Boyiadzis MM
Cancer
April 4, 2023Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia.
Fathi AT, Kim HT, Soiffer RJ, Levis MJ, Li S, Kim AS, DeFilipp Z, El-Jawahri A, McAfee SL, Brunner AM, Amrein PC, Mims AS, Knight LW, Kelley D, Bottoms AS, Perry LH, Wahl JL, Brock J, Breton E, Marchione DM, Ho VT, Chen YB
Clin Cancer Res
December 21, 2022TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion.
Eisenmann ED, Stromatt JC, Fobare S, Huang KM, Buelow DR, Orwick S, Jeon JY, Weber RH, Larsen B, Mims AS, Hertlein E, Byrd JC, Baker SD
Cancers (Basel)
November 18, 2022North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need.
Pemmaraju N, Kantarjian HM, Sweet KL, Wang ES, Senapati J, Wilson NR, Konopleva MY, Frankel AE, Gupta V, Mesa RA, Ulrickson ML, Gorak E, Bhatia S, Budak-Alpdogan T, Mason JR, Garcia-Romero MT, Lopez-Santiago NC, Cesarman-Maus G, Vachhani P, Lee S, Bhatt VR, Blum W, Walter RB, Bixby D, Gojo I, Duvic M, Rampal RK, de Lima M, Foran JM, Fathi AT, Hall A, Jacoby MA, Lancet JE, Mannis GN, Stein AS, Mims AS, Rizzieri D, Olin RL, Perl AE, Schiller GJ, Shami PJ, Stone RM, Strickland S, Wieduwilt MJ, Daver NG, Ravandi F, Vasu S, Guzman ML, Roboz GJ, Khoury JD, Qazilbash MH, Aung P, Cuglievan B, Madanat YF, Kharfan-Dabaja MA, Pawlowska AB, Taylor J, Tallman MS, Dhakal P, Lane AA
Blood
November 14, 2022Longitudinal Survival Outcomes in Allogeneic Stem Cell Transplantation: An Institutional Experience.
Jiang J, Sigmund AM, Zhao Q, Elder P, Benson DM, Vasu S, Jaglowski S, Mims A, Choe H, Larkin K, Brammer JE, Wall S, Grieselhuber N, Saad A, Penza S, Efebera YA, Sharma N
Cancers (Basel)
October 31, 2022Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.
Saliba AN, Kaufmann SH, Stein EM, Patel PA, Baer MR, Stock W, Deininger MW, Blum W, Schiller GJ, Olin RL, Litzow MR, Lin TL, Ball BJ, Boyiadzis M, Traer E, Odenike O, Arellano ML, Walker AR, Duong VH, Kovacsovics TJ, Collins RH, Shoben AB, Heerema NA, Foster MC, Peterson KL, Schneider PA, Martycz M, Gana T, Rosenberg L, Marcus S, Yocum AO, Chen TL, Stefanos M, Mims AS, Borate U, Burd A, Druker BJ, Levine RL, Byrd JC, Foran JM
Blood Adv
October 12, 2022Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance.
Lyu J, Liu Y, Gong L, Chen M, Madanat YF, Zhang Y, Cai F, Gu Z, Cao H, Kaphle P, Kim YJ, Kalkan FN, Stephens H, Dickerson KE, Ni M, Chen W, Patel P, Mims AS, Borate U, Burd A, Cai SF, Yin CC, You MJ, Chung SS, Collins RH, DeBerardinis RJ, Liu X, Xu J
Cancer Discov
September 23, 2022Enasidenib as Maintenance following Allogeneic Hematopoietic Cell Transplantation for IDH2-Mutated Myeloid Malignancies.
Fathi AT, Kim HT, Soiffer RJ, Levis MJ, Li S, Kim AS, Mims AS, DeFilipp Z, El-Jawahri A, McAfee SL, Brunner AM, Narayan R, Knight LW, Kelley D, Bottoms AS, Perry LS, Wahl JL, Brock J, Breton E, Ho VT, Chen YB
Blood Adv
July 5, 2022High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML.
Larkin K, Nicolet D, Kelly BJ, Mrózek K, LaHaye S, Miller KE, Wijeratne S, Wheeler GL, Kohlschmidt J, Blachly JS, Mims AS, Walker C, Oakes CC, Orwick S, Boateng I, Buss J, Heyrosa A, Desai H, Carroll AJ, Blum W, Powell BL, Kolitz JE, Moore JO, Mayer RJ, Larson RA, Stone RM, Paskett ED, Byrd JC, Mardis E, Eisfeld AK
Blood Adv
May 2, 2022Venetoclax and acute myeloid leukaemia: an expanding new frontier.
Sahasrabudhe KD, Mims AS
Lancet Haematol
April 5, 2022Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation.
Bill M, Jentzsch M, Bischof L, Kohlschmidt J, Grimm J, Schmalbrock LK, Backhaus D, Brauer D, Goldmann K, Franke GN, Vucinic V, Niederwieser D, Mims AS, Platzbecker U, Eisfeld AK, Schwind S
Blood Adv
March 23, 2022Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination.
Eisenmann ED, Garrison DA, Talebi Z, Jin Y, Silvaroli JA, Kim JG, Sparreboom A, Savona MR, Mims AS, Baker SD
Pharmaceutics
January 1, 2022Impact of Race and Geographic Area of Residence on Outcomes After Allogeneic Stem Cell Transplant.
Sigmund AM, Zhao Q, Jiang J, Elder P, Benson DM, Rosko A, Bumma N, Khan A, Devarakonda S, Vasu S, Jaglowski S, Mims A, Choe H, Larkin K, Brammer J, Wall S, Grieselhuber N, Saad A, Penza S, Efebera YA, Sharma N
Front Oncol
January 1, 2022Editorial: Rising Stars in Hematologic Malignancies 2021.
Qian L, De Lima M, Mims AS, Epperla N
Front Oncol
November 30, 2021Molecular associations, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia (Alliance).
Fobare S, Kohlschmidt J, Ozer HG, Mrózek K, Nicolet D, Mims AS, Garzon R, Blachly JS, Orwick S, Carroll AJ, Stone RM, Wang ES, Kolitz JE, Powell BL, Oakes CC, Eisfeld AK, Hertlein E, Byrd JC
Blood Adv
November 17, 2021PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in Acute Myeloid Leukemia.
Goswami S, Mani R, Nunes J, Chiang CL, Zapolnik K, Hu EY, Frissora FW, Mo XM, Walker LA, Yan PS, Bundschuh R, Beaver L, Devine RD, Tsai YT, Ventura AM, Xie Z, Chen M, Lapalombella R, Walker AR, Mims AS, Larkin K, Grieselhuber NR, Bennett C, Phelps MA, Hertlein E, Behbehani GK, Vasu S, Byrd JC, Muthusamy N
Blood
November 13, 2021Off the Shelf Third Party Virus Specific T-Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplant Recipients.
Rubinstein JD, Jodele S, Heyenbruch D, Wilhelm J, Thomas S, Lutzko C, Zhu X, Leemhuis T, Cancelas JA, Keller M, Bollard CM, Hanley PJ, Boghdadly ZE, Mims A, Davies SM, Grimley MS, Nelson AS
Transplant Cell Ther
October 28, 2021Diagnostic utility of bronchoscopy in newly diagnosed acute leukemia patients.
Koenig KL, Curley TP, Mani S, Keiter A, Zhao Q, Behbehani GK, Bhatnagar B, Blachly JS, Haque TZ, Larkin KTM, Long M, Mims AS, Vasu S, Wall SA, Byrd JC, Lustberg M, Walker AR, Grieselhuber NR
Hematol Oncol
August 15, 2021A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Uckun FM, Lin TL, Mims AS, Patel P, Lee C, Shahidzadeh A, Shami PJ, Cull E, Cogle CR, Watts J
Cancers (Basel)
August 1, 2021Is venetoclax the new backbone of acute myeloid leukaemia therapy?
Jain P, Mims AS
Lancet Haematol
June 27, 2021Outcomes of Bone Marrow Compared to Peripheral Blood for Haploidentical Transplantation.
Sharma N, Faisal MS, Zhao Q, Jiang J, Elder P, Benson DM, Rosko A, Chaudhry M, Bumma N, Khan A, Devarakonda S, Vasu S, Jaglowski S, Mims AS, Choe H, Larkin K, Brammer JE, Wall S, Grieselhuber N, Saad A, Penza S, Sigmund AM, Efebera YA
J Clin Med
June 23, 2021A precision medicine classification for treatment of acute myeloid leukemia in older patients.
Mims AS, Kohlschmidt J, Borate U, Blachly JS, Orwick S, Eisfeld AK, Papaioannou D, Nicolet D, Mr?zek K, Stein E, Bhatnagar B, Stone RM, Kolitz JE, Wang ES, Powell BL, Burd A, Levine RL, Druker BJ, Bloomfield CD, Byrd JC
J Hematol Oncol
May 21, 2021Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq.
Saygin C, Hu E, Zhang P, Sher S, Lozanski A, Doong TJ, Nicolet D, Orwick S, Labanowska J, Skinner JN, Cempre C, Kauffman T, Goettl VM, Heerema NA, Abruzzo L, Miller C, Lapalombella R, Behbehani G, Mims AS, Larkin K, Grieselhuber N, Walker A, Bhatnagar B, Bloomfield CD, Byrd JC, Lozanski G, Blachly JS
Leukemia
March 24, 2021Type of prior genotoxic insult determines the genomic characteristics of therapy-related myeloid neoplasms.
Ozga M, Blachly J, Eisfeld AK, Grieselhuber N, Larkin K, Walker A, Bhatnagar B, Behbehani G, Long M, Haque T, Vasu S, Zhao W, Jones D, Byrd JC, Mims AS, Saygin C
Am J Hematol
March 18, 2021Novel Targeted Therapeutics in Acute Myeloid Leukemia: an Embarrassment of Riches.
Grieselhuber NR, Mims AS
Curr Hematol Malig Rep
February 25, 2021Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
Chen EC, Li S, Eisfeld AK, Luskin MR, Mims A, Jones D, Antin JH, Cutler CS, Koreth J, Ho VT, Gooptu M, Romee R, El-Jawahri A, McAfee SL, DeFilipp Z, Soiffer RJ, Chen YB, Fathi AT
Transplant Cell Ther
February 4, 2021Targeting DNA damage repair functions of two histone deacetylases, HDAC8 and SIRT6, sensitizes acute myeloid leukemia to NAMPT inhibition.
Zhang P, Brinton LT, Williams K, Sher S, Orwick S, Lai TH, Mims AS, Coss CC, Kulp SK, Youssef Y, Chan WK, Mitchell S, Mustonen A, Cannon M, Phillips H, Lehman AM, Kauffman T, Beaver L, Canfield D, Grieselhuber NR, Alinari L, Sampath D, Yan P, Byrd JC, Blachly JS, Lapalombella R
Clin Cancer Res
February 4, 2021Effect of Early Post-Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation.
Sharma N, Zhao Q, Ni B, Elder P, Puto M, Benson DM, Rosko A, Chaudhry M, Devarakonda S, Bumma N, Khan A, Vasu S, Jaglowski S, William BM, Mims A, Choe H, Larkin K, Brammer J, Wall S, Grieselhuber N, Saad A, Penza S, Efebera Y
Cancers (Basel)
January 6, 2021NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
Pollyea DA, Bixby D, Perl A, Bhatt VR, Altman JK, Appelbaum FR, de Lima M, Fathi AT, Foran JM, Gojo I, Hall AC, Jacoby M, Lancet J, Mannis G, Marcucci G, Martin MG, Mims A, Neff J, Nejati R, Olin R, Percival ME, Prebet T, Przespolewski A, Rao D, Ravandi-Kashani F, Shami PJ, Stone RM, Strickland SA, Sweet K, Vachhani P, Wieduwilt M, Gregory KM, Ogba N, Tallman MS
J Natl Compr Canc Netw
January 1, 2021Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA.
Watts J, Lin TL, Mims A, Patel P, Lee C, Shahidzadeh A, Shami P, Cull E, Cogle CR, Wang E, Uckun FM
Front Oncol
December 4, 2020Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia.
Bhatnagar B, Kohlschmidt J, Mrózek K, Zhao Q, Fisher JL, Nicolet D, Walker CJ, Mims AS, Oakes C, Giacopelli B, Orwick S, Boateng I, Blachly JS, Maharry SE, Carroll AJ, Powell BL, Kolitz JE, Stone RM, Byrd JC, Paskett ED, de la Chapelle A, Garzon R, Eisfeld AK
Cancer Discov
November 24, 2020Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS.
Rasor B, Dickerson T, Zhao Q, Elder P, Brammer JE, Larkin K, Jaglowski S, Mims A, Penza S, Vasu S, Wall SA, William B, Saad A, Roddy JVF, Choe H, Puto M
Leuk Lymphoma
October 26, 2020Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.
Burd A, Levine RL, Ruppert AS, Mims AS, Borate U, Stein EM, Patel P, Baer MR, Stock W, Deininger M, Blum W, Schiller G, Olin R, Litzow M, Foran J, Lin TL, Ball B, Boyiadzis M, Traer E, Odenike O, Arellano M, Walker A, Duong VH, Kovacsovics T, Collins R, Shoben AB, Heerema NA, Foster MC, Vergilio JA, Brennan T, Vietz C, Severson E, Miller M, Rosenberg L, Marcus S, Yocum A, Chen T, Stefanos M, Druker B, Byrd JC
Nat Med
October 13, 2020Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome.
Kittai AS, Bond DA, William B, Saad A, Penza S, Efebera Y, Larkin K, Wall SA, Choe HK, Bhatnagar B, Vasu S, Brammer J, Shindiapina P, Long M, Mims A, O'Donnell L, Bhat SA, Rogers KA, Woyach JA, Byrd JC, Jaglowski SM
Blood Adv
September 5, 2020Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Stein EM, DiNardo CD, Fathi AT, Mims AS, Pratz KW, Savona MR, Stein AS, Stone RM, Winer ES, Seet CS, Döhner H, Pollyea DA, McCloskey J, Odenike O, Löwenberg B, Ossenkoppele GJ, Patel PA, Roshal M, Frattini MG, Lersch F, Franovic A, Nabhan S, Fan B, Choe S, Wang H, Wu B, Hua L, Almon C, Cooper M, Kantarjian HM, Tallman MS
Blood
September 4, 2020Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia.
Underwood B, Zhao Q, Walker AR, Mims AS, Vasu S, Long M, Z Haque T, Blaser BW, Grieselhuber NR, Wall SA, Behbehani GK, Blachly JS, Larkin K, Byrd JC, Garzon R, Wang TF, Bhatnagar B
Int J Hematol Oncol
September 1, 2020CD33-Targeted Therapies: Beating the Disease or Beaten to Death?
Maakaron JE, Rogosheske J, Long M, Bachanova V, Mims AS
J Clin Pharmacol
August 20, 2020Entospletinib in Combination With Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 expression.
Walker A, Byrd JC, Blachly JS, Bhatnagar B, Mims A, Orwick S, Lin TL, Crosswell HE, Zhang D, Minden MD, Munugalavadla V, Long L, Liu J, Pan Y, Oellerich T, Serve H, Rao AV, Blum WG
Clin Cancer Res
August 10, 2020A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Saygin C, Larkin K, Blachly JS, Orwick S, Ngankeu A, Gregory CT, Phelps MA, Mani S, Walker A, Garzon R, Vasu S, Walsh KJ, Bhatnagar B, Klisovic RB, Grever MR, Marcucci G, Byrd JC, Blum W, Mims AS
Am J Hematol
August 5, 2020Comparison of clinical and molecular characteristics of patients with acute myeloid leukemia and either TP73 or TP53 mutations.
Mims AS, Kohlschmidt J, Eisfeld AK, Mr?zek K, Blachly JS, Orwick S, Papaioannou D, Nicolet D, Sampath D, Stone RM, Powell BL, Kolitz JE, Byrd JC, Bloomfield CD
Leukemia
July 30, 2020Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results.
Heuser M, Palmisiano N, Mantzaris I, Mims A, DiNardo C, Silverman LR, Wang ES, Fiedler W, Baldus C, Schwind S, Pardee T, Perl AE, Cai C, Kaulfuss S, Lagkadinou E, Rentzsch C, Wagner M, Wilkinson G, Wu B, Jeffers M, Genvresse I, Krämer A
Leukemia
May 27, 2020Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years.
Eisfeld AK, Kohlschmidt J, Mims A, Nicolet D, Walker CJ, Blachly JS, Carroll AJ, Papaioannou D, Kolitz JE, Powell BE, Stone RM, de la Chapelle A, Byrd JC, Mrózek K, Bloomfield CD
Leukemia
May 12, 2020Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML.
Choe S, Wang H, DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Watts JM, Pollyea DA, Fathi AT, Tallman MS, Kantarjian HM, Stone RM, Quek L, Konteatis Z, Dang L, Nicolay B, Nejad P, Liu G, Zhang V, Liu H, Goldwasser M, Liu W, Marks K, Bowden C, Biller SA, Attar EC, Wu B
Blood Adv
May 6, 2020Hypomethylating agents super-responders: challenging the dogma of long-term remission for acute myeloid leukemia.
Maakaron JE, Ozga MP, Mannis GN, Pulley W, Foster MC, Zeidner JF, Mims AS
Ann Hematol
Consulting and Related Relationships
More info forAt The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Mims has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.
- Rigel Pharmaceuticals
- Bristol Myers Squibb
- AbbVie
- Vincerx Pharma
- Foghorn Therapeutics Inc
- Notable Labs, Inc
- Treadwell Therapeutics
Patient Comments
Dr Mims is a wonderful, caring doctor who inspires trust. She is always there for me. I am blessed to be cared for by such an amazing doctor.
Friendly, professional, and respectful!
Good
Dr. Mims is my care provider. She is an excellent Doctor. She takes her time with you and makes sure you get everything you need. I would recommend Dr. Mims and the James to everyone.
Best care, my experience at OSU since 2017 has been the best, I my alive today thanks to them
Dr Mims and her staff very good happy Dr Mims is my doctor
Loved Dr Mims
Dr. Mims is excellent!
The care I receive from Dr. Mims and the staff at the James is fantastic. From scheduling my appointment to meeting with my Doctor I get great care. I would recommend this hospital to everyone.
All good.
Dr. Alice Mims is a great asset to the James, and the hematology department. I have a great level of trust in her care and capabilities.
Dr. Mims & staff are all very nice & caring. I would highly recommend her to others.